

Food and Drug Administration Silver Spring MD 20993

NDA 207114 NADA 141432

DEEMED GRANTED - MEDICAL GAS CERTIFICATION REQUEST

American Welding & Gas, Inc. Attn: Andreas Boone Safety and Compliance Director 320 North 11th Street Billings, MT 59101

Dear Mr Boone:

Please refer to your March 5, 2014, request received on March 13, 2014, for certification of Medical Air, USP as a designated medical gas. You have requested to market Medical Air, USP for human and animal drug use.

A request for certification of a medical gas as a designated medical gas submitted under section 575(a)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) is deemed to be granted unless, within 60 days of the filing of the request, FDA finds that one or more of the bases for denying the request listed at section 575(a)(2) of the FD&C Act applies. FDA has made no such finding in connection with your request, and 60 days have passed since your request was filed. Accordingly, by operation of section 575(a)(2) of the FD&C Act, your request for certification of Medical Air, USP as a designated medical gas is deemed to be granted, and you now have in effect an approved new drug application (NDA 207114) and an approved new animal drug application (NADA 141432) for this gas.

If any of the information you have submitted in connection with your request becomes incomplete or inaccurate, please consult section IV.D of the draft guidance document entitled *Certification Process for Designated Medical Gases* (available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM332136.pdf) for instructions on providing FDA with complete, up-to-date information. Please address any such communications to:

Food and Drug Administration Center for Drug Evaluation and Research Office of Pharmaceutical Quality 5901-B Ammendale Road Beltsville, MD 20705-1266 NDA 207114 NADA 141432 Page 2

Please include the NDA and NADA numbers listed above at the top of the first page of any such communications.

If you have any questions, please contact Michael Folkendt at (301) 796-1670 or by email at michael.folkendt@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Charles J. Andres, Ph.D.
Business Process Improvement Manager
Office of New Animal Drug Evaluation
Center for Veterinary Medicine
FDA

Michael Folkendt Associate Director for Regulatory Affairs Office of Program and Regulatory Operations Office of Pharmaceutical Quality Center for Drug Evaluation and Research FDA

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.	
/s/	
MICHAEL M FOLKENDT 09/25/2015	

CHARLES J ANDRES 09/28/2015

7